Investors sold shares of Allergan PLC (NYSE:AGN) on strength during trading hours on Thursday. $123.68 million flowed into the stock on the tick-up and $141.79 million flowed out of the stock on the tick-down, for a money net flow of $18.11 million out of the stock. Of all companies tracked, Allergan PLC had the 0th highest net out-flow for the day. Allergan PLC traded up $3.22 for the day and closed at $237.76

A number of equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. restated an “overweight” rating on shares of Allergan PLC in a report on Friday, May 13th. Credit Suisse Group AG assumed coverage on shares of Allergan PLC in a report on Monday, July 25th. They issued an “outperform” rating and a $327.00 target price on the stock. Zacks Investment Research lowered shares of Allergan PLC from a “buy” rating to a “hold” rating in a report on Tuesday, July 26th. Vetr lowered shares of Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $283.05 target price on the stock. in a report on Monday, August 8th. Finally, Leerink Swann set a $294.00 target price on shares of Allergan PLC and gave the company a “buy” rating in a report on Monday, August 8th. Six equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $309.13.

The company has a market capitalization of $94.14 billion and a price-to-earnings ratio of 22.64. The firm’s 50-day moving average price is $248.32 and its 200-day moving average price is $247.69.

Allergan PLC (NYSE:AGN) last issued its quarterly earnings data on Monday, August 8th. The company reported $3.35 EPS for the quarter, topping analysts’ consensus estimates of $3.34 by $0.01. During the same period in the prior year, the firm posted $4.41 earnings per share. The company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $4.10 billion. The business’s revenue for the quarter was up 1.0% on a year-over-year basis. Equities research analysts expect that Allergan PLC will post $14.00 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Allergan PLC stock. Schwab Charles Investment Management Inc. increased its stake in Allergan PLC (NYSE:AGN) by 4.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,069,878 shares of the company’s stock after buying an additional 40,665 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.27% of Allergan PLC worth $334,337,000 as of its most recent SEC filing.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.